Literature DB >> 3349496

Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson's disease.

J I Sage1, L Schuh, R E Heikkila, R C Duvoisin.   

Abstract

Four parkinsonian patients received continuous duodenal infusions of levodopa (LD) for severe "on-off" phenomena associated with Sinemet (carbidopa/levodopa) therapy. All patients had marked decreases in motor fluctuations on the infusions compared with tablets. Two factors that appear related to this improvement are the ability of duodenal infusions to produce steadier plasma LD concentrations and/or to maintain LD concentrations above a minimum threshold needed to achieve the "on" state.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3349496

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  13 in total

1.  Pharmacokinetics and effects of levodopa in advanced Parkinson's disease.

Authors:  E Bredberg; J Tedroff; S M Aquilonius; L Paalzow
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  The on-off phenomenon.

Authors:  A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

3.  Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa/carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa.

Authors:  D Deleu; G Ebinger; Y Michotte
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  The influence of levodopa on gastric emptying in man.

Authors:  D R Robertson; A G Renwick; N D Wood; N Cross; B S Macklin; J S Fleming; D G Waller; C F George
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

Review 5.  Current drug therapy for Parkinson's disease. A review.

Authors:  R J Coleman
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

6.  Levodopa availability improves with progression of Parkinson's disease.

Authors:  Dirk Woitalla; Oliver Goetze; Jeong I Kim; Alice B Nikodem; Wolfgang E Schmidt; Horst Przuntek; Thomas Müller
Journal:  J Neurol       Date:  2006-04-28       Impact factor: 4.849

Review 7.  Using liquid levodopa in the treatment of Parkinson's disease. A practical guide.

Authors:  M C Kurth
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

8.  Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease.

Authors:  E Bredberg; D Nilsson; K Johansson; S M Aquilonius; B Johnels; C Nyström; L Paalzow
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

9.  Pharmacokinetics of levodopa and carbidopa in rats following different routes of administration.

Authors:  E Bredberg; H Lennernäs; L Paalzow
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

10.  Continuous levodopa for advanced Parkinson's disease.

Authors:  Christofer Lundqvist
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.